Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
$121.93
-$1.54(-1.52%)
At close: 4:00 PM EST
$121.93
-$1.54(-1.52%)
Day’s Range― - ―
52-Week Range$73.31 - $122.66
Previous CloseN/A
Volume3.30M
Average Volume (3M)12.58M
Market Cap
$302.63B
Enterprise Value$293.79B
Total Cash (Recent Filing)$18.21B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)16.7
Beta0.55
Next Earnings
Apr 30, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend Yield3.12%
Share Statistics
EPS (TTM)2.04
Shares Outstanding2,482,022,500
10 Day Avg. Volume16,076,689
30 Day Avg. Volume12,578,832
Financial Highlights & Ratios
PEG Ratio1.88
Price to Book (P/B)5.08
Price to Sales (P/S)4.06
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda10.20
Forecast
1Y Price Target
$123.63Price Target Upside1.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Readouts And ApprovalsAnalyst notes multiple late-stage clinical trial readouts across the portfolio could provide substantial upside if results support regulatory approvals and commercial launches.
Patent Protection For Flagship TherapyCompany confidence in securing patent extensions for its leading immunotherapy would help smooth revenue declines from loss of exclusivity and support valuation.
Strategic Acquisitions And Business DevelopmentAnalyst highlights management's willingness to pursue sizable acquisitions and targeted business development, which could accelerate pipeline transformation and diversify revenue sources.
Bears Say
Acquisition-related Charges And Accounting EffectsA significant one-time charge and complex profit-and-loss dynamics tied to a recent acquisition will weigh on reported earnings and may reduce near-term shareholder support.
Revenue Guidance And Mature-product HeadwindsA lower-than-expected revenue outlook driven partly by declines in late-life products and one-time impacts may temper investor expectations and pressure the stock.
Vaccine Demand And Competitor InventorySoftness in vaccine demand and excess competitor inventory has reduced uptake of recent respiratory launches, creating a risk of prolonged sales headwinds.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $122.66 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $302.63B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 30, 2026 which is in 79 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 03, 2026. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.011 by $0.029.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 3.12%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is -1.5.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,482,022,500 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.04 in its last earnings report, beating expectations of $2.011. Following the earnings report the stock price went up 2.179%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.63 (1.39% Upside)
$123.63 (1.39% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 736.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances near-term challenges (a sizable one-time Sidera acquisition charge, meaningful vaccine softness — notably Gardasil down 35% — RSV uptake below expectations, and an identified ~$2.5B headwind from generics and pricing reforms) against clear commercial and pipeline momentum (5% Q4 revenue growth, KEYTRUDA resilience, multiple high-growth product launches, strong specialty product performance, animal health growth, completed strategic acquisitions, and a materially expanded long‑term commercial opportunity with numerous near-term clinical readouts and regulatory milestones). While 2026 reported EPS and margins are being impacted by the acquisition charge and short-term pressures, management emphasizes durable long-term growth driven by a deep pipeline and new product launches, positioning the company for stronger growth beyond the LOE period.View all MRK earnings summariesMRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$123.63
▲(1.39% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
20.20% Mutual Funds
0.43% Other Institutional Investors
55.08% Public Companies and Individual Investors